Novartis vs Bristol-Myers Squibb: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novartis AG (NOVN.SW)

Q3 202628 Jun – 2 Oct 2026

▲2▼2

Novartis Q3: new drugs and deals offset generic hit and pipeline setbacks

New drug approvals and acquisition EU approved Itvisma gene therapy and FDA fully approved Fabhalta for kidney disease. Novartis also bought Myricx Bio for $1.5 billion, adding new treatments to its portfolio.
These approvals and the acquisition are new positive events that can drive future sales and growth.
Earnings beat and pipeline progress Q2 earnings beat expectations with sales returning to growth. Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing, and licensing deals worth up to $8.1 billion plus Sironax acquisition signaled continued innovation investment.
Earnings beat and pipeline advancements are new positive developments that support investor confidence.
Entresto sales plunge on generics Entresto sales plunged 50% due to generic competition, a $4 billion annual hit. This major revenue loss weighs on the stock.
This is a new negative event that directly impacts Novartis's revenue and profitability.
Pipeline setbacks and governance concerns CAR-T trials paused after three deaths; pelacarsen and del-desiran failed late-stage trials; rifonebart was halted. UBS turned cautious, and top shareholder Artisan Partners demanded a board overhaul amid $39.4 billion net debt and governance concerns.
These new negative events raise safety, efficacy, and governance issues that can hurt investor sentiment.

September 20267 Sep – 2 Oct 2026

▼2▲1

Pipeline failures and governance pressure hit Novartis in September

Late-stage trial failures Pelacarsen and del-desiran failed late-stage trials, erasing billions in potential revenue and market value, while ALS drug rifonebart was halted. These setbacks hurt sentiment and raised doubts about the pipeline.
Major negative news that directly impacted investor confidence and valuation.
Governance pressure from top shareholder Top shareholder Artisan Partners demanded a board overhaul over dealmaking, with net debt at $39.4 billion and eight shareholders raising concerns. This adds uncertainty about strategy and capital allocation.
Governance issues can weigh on stock price and investor trust.
Pipeline wins and licensing deals Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing for polymyalgia rheumatica, and Novartis signed licensing deals worth up to $8.1 billion plus acquired Sironax's brain-delivery platform, signaling continued investment in innovation.
Positive pipeline news and deals support future growth despite recent failures.

Latest22 Sep – 2 Oct 2026

▲2▼2

Novartis adds two big pipeline deals; board pressure and CAR-T pause persist

Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.
These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.
Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.
It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.
CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.
It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.
EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.
It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

7 Sep – 18 Sep 2026

▲2▼2

Novartis hit by three trial failures; pipeline doubts deepen

ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.
New pipeline failure that directly adds to negative sentiment and future growth doubts.
Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.
New deal that shows continued pipeline investment and a small positive counterweight.
EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.
New regulatory win that broadens an existing product's label and provides a positive offset.
Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.
New details on activist pressure and balance-sheet strain that affect investor confidence.

7 Sep – 11 Sep 2026

▼3▲1

Novartis hit by two trial failures, board pressure; MS drug offers hope

Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.
This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.
Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.
This is the biggest new negative event, causing a record share drop and directly impacting valuation.
Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.
This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.
Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.
This is the main positive counterweight, showing pipeline strength and potential to offset losses.

August 20266 Aug – 4 Sep 2026

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.
A major safety setback that directly threatens a key pipeline and investor confidence.
Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.
The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.
Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.
A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.
Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.
A new partnership that supports future product lifecycles and is not already covered.

6 Aug – 4 Sep 2026

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.
A major safety setback that directly threatens a key pipeline and investor confidence.
Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.
The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.
Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.
A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.
Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.
A new partnership that supports future product lifecycles and is not already covered.

July 202628 Jun – 23 Jul 2026

▲4▼2

Novartis pipeline wins and earnings beat offset Entresto decline

EU approval for Itvisma gene therapy Novartis received EU approval for its Itvisma gene therapy, adding a new treatment option and reinforcing its position in advanced therapies. This expands the company's portfolio and offers a potential new revenue stream.
This is a new regulatory win that supports future growth.
FDA full approval for Fabhalta in kidney disease The FDA granted full approval for Fabhalta in kidney disease, transitioning from accelerated approval. This validates the drug's efficacy and allows broader marketing, potentially boosting sales in a new indication.
This is a new regulatory milestone that could drive revenue.
$1.5B Myricx Bio acquisition Novartis acquired Myricx Bio for $1.5 billion, adding a new asset to its pipeline. This strategic move aims to bolster future growth through external innovation.
This is a new acquisition that expands the pipeline.
Q2 earnings beat with sales returning to growth Novartis reported Q2 earnings that beat expectations, with sales returning to growth despite Entresto's decline. This shows resilience and operational execution, reassuring investors about the company's trajectory.
This is a new financial result that positively surprised the market.
Entresto sales plunge 50% on generics Entresto sales fell 50% as generic competition entered the market, resulting in a $4 billion annual revenue hit. This significant loss pressures overall growth and profitability.
This is a new negative development impacting financials.
UBS turns cautious on Novartis relative to peers UBS downgraded its view on Novartis, citing relative underperformance compared to AstraZeneca and Roche. This cautious stance may limit upside and affect investor sentiment.
This is a new analyst action that could weigh on the stock.
High-stakes late-stage trials could add $10B+ but face failure risk Three late-stage trials (pelacarsen, remibrutinib, del-desiran) could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates meaningful pipeline uncertainty.
This is a new analyst warning about pipeline risk.

16 Jul – 23 Jul 2026

▲2▼1

Novartis wins FDA label expansions, Q2 beat, but Entresto cliff and pipeline risk loom

FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.
This is a new regulatory win that directly boosts Novartis's revenue outlook.
Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.
The earnings beat is a new event that shows the company's core business is performing better than expected.
Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.
This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.
Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.
This highlights the key risk and potential reward that will drive the stock's longer-term direction.

28 Jun – 9 Jul 2026

▲3▼1

Novartis advances gene therapy and oncology pipeline, but UBS turns cautious

EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.
This is a concrete regulatory win that directly adds a new approved product and potential sales.
Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.
This is a major strategic deal that bolsters the pipeline and signals growth investment.
ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.
This points to a significant pipeline opportunity that could drive future revenue.
UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.
This is a direct analyst opinion that could influence investor perception and relative performance.

Q2 202618 Jun – 26 Jun 2026

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.
This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.
Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.
New clinical success expands the pipeline and boosts confidence in future revenue.
Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.
New positive trial data for a potential first-in-class therapy supports long-term growth.
Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.
New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

June 202618 Jun – 26 Jun 2026

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.
This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.
Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.
New clinical success expands the pipeline and boosts confidence in future revenue.
Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.
New positive trial data for a potential first-in-class therapy supports long-term growth.
Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.
New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

18 Jun – 26 Jun 2026

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.
This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.
Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.
New clinical success expands the pipeline and boosts confidence in future revenue.
Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.
New positive trial data for a potential first-in-class therapy supports long-term growth.
Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.
New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

Bristol-Myers Squibb Company (BMY)

Q3 202610 Jul – 30 Sep 2026

▲3▼1

Bristol-Myers Q3: Pipeline Wins, Financial Beat, But Competitive and Legal Risks Loom

Strong Q2 results and raised guidance Bristol reported Q2 revenue of about $13 billion and a 40% jump in earnings per share, prompting management to raise full-year revenue guidance to $49–50 billion. Analysts also increased their 2026 EPS estimates to $6.91.
This shows the company's core financial performance and improved outlook, a key positive driver for the stock.
Pipeline and regulatory progress The FDA accepted mezigdomide for review, approved ZENBEXUS for multiple myeloma, and expanded Camzyos to treat pediatric patients. These advances strengthen Bristol's product lineup and help offset future patent losses.
New drug approvals and expanded uses are direct growth catalysts that can drive future sales and investor confidence.
AI and infrastructure investments Bristol partnered with NVIDIA, Schrödinger, and Chai Discovery on AI-driven drug discovery, and opened a new San Diego hub and Houston plant. These investments aim to speed up research and expand manufacturing capacity.
Long-term growth initiatives that could improve efficiency and innovation, supporting the stock's future potential.
Competitive and legal pressures Cytokinetics' Myqorzo threatens Camzyos, J&J's psoriasis pill challenges Sotyktu in China, and AstraZeneca merger talks collapsed. A $6.7B Celgene lawsuit revived, and CAR-T trials paused after Novartis deaths.
These setbacks create uncertainty and potential revenue loss, weighing on the stock price.

September 202628 Aug – 30 Sep 2026

▲2▼2

BMY pipeline advances, but competition and safety concerns weigh

Pipeline and label expansion Zenbexus won FDA accelerated approval for relapsed multiple myeloma, Camzyos expanded to pediatric patients, and Arlo-cel met its Phase 2 endpoint, strengthening BMY's growth prospects.
This is a key positive development that could drive future revenue and investor optimism.
Analyst EPS estimate raise Growth products now make up 56% of revenue, leading analysts to raise 2026 EPS estimates to $6.91 from $6.34, reflecting confidence in BMY's earnings power.
This shows improved financial outlook and analyst confidence, which can positively impact the stock.
Competitive threat to Sotyktu J&J's oral psoriasis pill won Chinese approval, threatening Sotyktu in a market of over 8 million patients, potentially limiting BMY's growth in a key segment.
This competitive pressure could hurt BMY's market share and revenue, a negative for the stock.
CAR-T trial pause Bristol paused CAR-T trials after Novartis deaths, raising regulatory and safety concerns that could delay development and pressure the stock.
This introduces uncertainty and potential setbacks in a promising area, negatively impacting investor sentiment.

Latest18 Sep – 30 Sep 2026

▲4

Bristol's Growth Portfolio Accelerates with New Drug Approvals and Strong Pipeline Data

Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.
Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.
Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.
A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.
Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.
Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.
Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.
Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

28 Aug – 8 Sep 2026

▲3▼2

Bristol's Cancer Pipeline Advances, but Competition and Safety Fears Linger

Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.
This is a new drug approval that directly adds a future revenue driver for BMY.
J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.
New competitive threat in a key market that could slow BMY's psoriasis drug sales.
Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.
New clinical data that supports the durability and safety of a key growth drug.
CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.
New safety event that directly affects BMY's CAR-T development and investor risk perception.
Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.
New positive clinical trial result that advances a potential new therapy for BMY.

August 202626 Jul – 21 Aug 2026

▲2▼2

BMY beats on earnings, raises guidance, but merger talks collapse

Strong Q2 earnings and raised guidance Bristol-Myers Squibb reported Q2 revenue of about $13 billion, beating estimates, with earnings per share jumping 40% to $2.04. Management raised full-year guidance twice, ending at $49–50 billion, driven by Eliquis (+19%) and newer drugs like Camzyos and Reblozyl.
This is the main positive force behind BMY's stock in August, showing better-than-expected financial performance and improved outlook.
FDA approves ZENBEXUS and AI partnerships expand The FDA approved ZENBEXUS for multiple myeloma, adding a new treatment to Bristol's portfolio. The company also expanded AI partnerships with Nvidia, Schrödinger, and Chai Discovery, and announced a $2.3 billion Houston plant, supporting long-term growth.
These new developments strengthen BMY's pipeline and manufacturing, offering future revenue potential.
AstraZeneca merger talks collapse Reported merger talks with AstraZeneca fell apart, removing a potential takeover premium that had lifted BMY's stock. Without a merger, Bristol faces its patent cliff alone, increasing pressure to replace lost revenue from older drugs.
This is a major negative event that removed a catalyst and leaves BMY more vulnerable to patent expirations.
Revived $6.7 billion Celgene lawsuit A $6.7 billion lawsuit related to the Celgene acquisition has been revived, adding legal and financial uncertainty. This could raise BMY's risk premium and pressure the stock as investors weigh potential liabilities.
This new legal issue introduces uncertainty and potential financial burden, negatively impacting investor sentiment.

15 Aug – 21 Aug 2026

▲3▼1

Bristol Raises Outlook, Expands AI and Manufacturing Despite Legal and Competitive Risks

Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.
This is the most significant new positive catalyst, directly raising revenue and profit outlook.
Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.
This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.
Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.
This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.
Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.
This new legal development introduces a significant potential liability, a negative factor for the stock.

26 Jul – 13 Aug 2026

▲3▼1

Bristol's Q2 Beat and New Drug Approval Offset Failed Merger

Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.
This is a major positive event that directly impacts BMY's financial outlook and investor confidence.
AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.
The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.
FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.
This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.
Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.
These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

2 Aug – 4 Aug 2026

▲2

Bristol Q2 Beat and AstraZeneca Merger Talk Lift BMY

Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.
This is the core fundamental news of the period and directly supports a higher valuation for BMY.
Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.
This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.
Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.
It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

July 202610 Jul – 23 Jul 2026

▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.
This is a new competitive threat that directly pressures a key BMY drug.
Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.
This is a new pricing agreement that directly affects BMY's revenue outlook.
FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.
This is a new regulatory milestone that advances a promising pipeline drug.
Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.
These new technology investments could enhance BMY's ability to develop new drugs faster.

10 Jul – 23 Jul 2026

▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.
This is a new competitive threat that directly pressures a key BMY drug.
Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.
This is a new pricing agreement that directly affects BMY's revenue outlook.
FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.
This is a new regulatory milestone that advances a promising pipeline drug.
Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.
These new technology investments could enhance BMY's ability to develop new drugs faster.

Q2 202617 Jun – 3 Jul 2026

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.
This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.
Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.
It is a new regulatory threat that could hurt BMY's reputation and operations.
Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.
It flags a new pricing risk that could lower BMY's future revenue.
Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.
It shows a new competitive loss that could reduce BMY's oncology revenue.

June 202617 Jun – 3 Jul 2026

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.
This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.
Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.
It is a new regulatory threat that could hurt BMY's reputation and operations.
Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.
It flags a new pricing risk that could lower BMY's future revenue.
Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.
It shows a new competitive loss that could reduce BMY's oncology revenue.

17 Jun – 3 Jul 2026

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.
This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.
Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.
It is a new regulatory threat that could hurt BMY's reputation and operations.
Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.
It flags a new pricing risk that could lower BMY's future revenue.
Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.
It shows a new competitive loss that could reduce BMY's oncology revenue.